Scarica l'app Stockscreener
3.52
8.31%
0.27
Dopo l'orario di chiusura:
3.60
0.08
+2.27%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
X 4 Pharmaceuticals Inc Borsa (XFOR) Ultime notizie
Director Moos Walter H was granted 2,500 shares, increasing direct ownership by 24% to 12,722 units (SEC Form 4) - Quantisnow
Director Hannah Alison L. was granted 2,500 shares, increasing direct ownership by 31% to 10,625 units (SEC Form 4) - Quantisnow
Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028 - Benzinga
SEC Form DEFA14A filed by Vanda Pharmaceuticals Inc. - Quantisnow
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Twinbeech Capital LP - MarketBeat
Layoff Tracker: Eikon Cuts Workforce by 15%, Citing ‘External Forces’ - BioSpace
President and CEO Polymeropoulos Mihael Hristos bought $43,995 worth of shares (10,000 units at $4.40), increasing direct ownership by 0.43% to 2,325,731 units (SEC Form 4) - Quantisnow
President and CEO Polymeropoulos Mihael Hristos bought $84,472 worth of shares (20,000 units at $4.22), increasing direct ownership by 0.87% to 2,315,731 units (SEC Form 4) - Quantisnow
23andMe to Be Bought by Regeneron Pharmaceuticals, a Biotech Company, for $256 Million - The New York Times
Bankrupt 23andMe Expected to Be Purchased for $256M - People.com
Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025 - Quantisnow
X4 Pharmaceuticals Announces Upcoming Presentation Of Phase 2 Chronic Neutropenia Trial Data At The 30Th Annual Eha Congress - marketscreener.com
X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress - marketscreener.com
X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data At the 30Th Annual Eha Congress - marketscreener.com
Xenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings Call Highlights: Strong Financial Position ... - Yahoo Finance
Fierce Biotech Layoff Tracker 2025: Insitro shrinks team by 22%; Shape ships out staff - Fierce Biotech
Renal Cell Carcinoma Pipeline Appears Robust With 30+ Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
What to Know About Eli Lilly’s Daily Pill for Weight Loss - The New York Times
HC Wainwright Raises X4 Pharmaceuticals (NASDAQ:XFOR) Price Target to $7.00 - Defense World
Director Hayden Michael R bought $477,900 worth of shares (15,000 units at $31.86), increasing direct ownership by 43% to 50,219 units (SEC Form 4) - Quantisnow
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - TradingView
X4 Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
XFOR: HC Wainwright Raises Price Target for X4 Pharmaceuticals | - GuruFocus
Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025 - Quantisnow
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2025 Earnings Call Transcript - Insider Monkey
X4 Pharmaceuticals Inc (XFOR) Q1 2025 Earnings Call Highlights: Progress in Maverick 4 ... - Yahoo Finance
X4 Pharmaceuticals Inc (XFOR) Q1 2025 Earnings Call Highlights: - GuruFocus
X4 Pharmaceuticals targets $1-2B U.S. market for mavorixafor in chronic neutropenia - MSN
X4 Pharmaceuticals Q1 2025 slides: XOLREMDI launch drives revenue beat amid pipeline progress - Investing.com India
Earnings call transcript: X4 Pharmaceuticals beats Q1 2025 EPS expectations - Investing.com Australia
Earnings call transcript: X4 Pharmaceuticals beats Q1 2025 EPS expectations By Investing.com - Investing.com UK
X4 Pharmaceuticals, Inc SEC 10-Q Report - TradingView
X4 Pharmaceuticals (XFOR) Posts Strong Q1 Results with Notable C - GuruFocus
X4 Pharmaceuticals: Q1 Earnings Snapshot - San Antonio Express-News
X4 Pharmaceuticals Inc (XFOR) Q1 2025 Earnings: EPS of $0.04 Bea - GuruFocus
XFOR Q1 Revenue Surges to $28.8 Million, Spotlighting Significan - GuruFocus
X4 Pharmaceuticals Full Enrollment On Track For 3Q Or 4Q 2025 And Top-Line Data In 2H 2026 - marketscreener.com
X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
XFORX4 Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan
Why X4 Pharmaceuticals, Inc. (XFOR) is Surging in 2025 - Insider Monkey
Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG - PR Newswire
X Marks the Spot: Challenges for Therapeutic Target Engagement in DBS - Psychiatric Times
Market Recap: X4 Pharmaceuticals Inc (XFOR)’s Positive Momentum, Closing at 0.19 - DWinneX
The Potential Rise in the Price of X4 Pharmaceuticals Inc (XFOR) following insiders activity - knoxdaily.com
Top 3 Health Care Stocks That May Rocket Higher In April - Benzinga
A look into X4 Pharmaceuticals Inc (XFOR)’s deeper side - Sete News
X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025 - marketscreener.com
X4 Pharmaceuticals Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - investchronicle.com
X4 Pharmaceuticals To Enact 1-for-30 Reverse Stock Split, Effective April 28, 2025 - Nasdaq
X4 Pharmaceuticals announces reverse stock split - Investing.com
X4 Pharmaceuticals Announces Reverse Stock Split - The Manila Times
X4 Pharmaceuticals Unveils Major 1-for-30 Stock Restructuring: Critical Nasdaq Compliance Plan Revealed - Stock Titan
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA - Quantisnow
Evaluating XFOR’s financial ratios for a profitable investment - uspostnews.com
X4 Pharmaceuticals Inc [XFOR] Investment Guide: What You Need to Know - knoxdaily.com
0.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):